Glaukos Corp

Glaukos insider buying signals confidence in its glaucoma injection pipeline, offering a potential entry point amid high social‑media buzz and a 52‑week low.

Insider sales at Glaukos show routine portfolio rebalancing, yet the firm’s micro‑injectable eye‑device pipeline, value‑based reimbursement prospects, and digital‑health integration shape its strategic risk‑reward profile.

Glaukos insider sells 1,074 shares at $97.02—an ordinary portfolio move, not a distress signal. Focus on its glaucoma drug pipeline, FDA milestones, and market dynamics for long‑term upside.

Glaukos insider trades reveal disciplined liquidity strategy amid promising GLO‑MIST trial results and FDA pre‑IND approval, hinting at future upside.